All In Biotech

Drug Trial Radar · NCT04702776

Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.

Non Inferiority Phase IV Clinical Study, to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF Against Hyabak® and Lagricel Ofteno® PF When Applied on the Ocular Surface of Patients With Mild to Moderate Dry Eye.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Dec 9, 2021

Primary completion

May 15, 2023

Study completion May 15, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in patients with mild to moderate dry eye disease.

Conditions

  • Dry Eye

Interventions

  • Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%Drug

    Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.

  • Sodium hyaluronate 0.15%Drug

    Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.

  • Sodium hyaluronate 0.4%Drug

    Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Ocular Surface Disease Index (OSDI)Time frame: Days: 0 (± 2) (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Unidad Clínica de Bioequivalencia, S. de R.L. de C.V.

    Guadalajara, Jalisco, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.